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ABSTRACT  
Ga68 labelled somatostatin receptor ligand PET imaging has recently been shown in 
preclinical and early human studies to have a potential role in the evaluation of vulnerable 
arterial plaques.  We prospectively evaluated carotid plaque Ga68-DOTATATE uptake in 
patients with recent carotid events, assessed inter- and intra- observer variability of such 
measurements, and explored the mechanism of any plaque DOTATATE activity with 
immunohistochemistry in resected specimens.   
 
Methods: 
20 consecutively consenting patients with recent symptomatic carotid events (transient 
ischaemic attack, stroke or amaurosis fugax), due for carotid endarterectomy were 
prospectively recruited. Ga68-DOTATATE PET/CT of the neck was performed prior to 
surgery.  Ga68-DOTATATE uptake was measured by drawing regions of interest (ROI) along 
the carotid plaques and contralateral plaques/carotid arteries by experienced radionuclide 
radiologist and radiographer. Two PET quantification methods with inter- and Intra-observer 
variability were assessed. Resected carotid plaques were retrieved for sst-2 
immunohistochemical stain.  
 
Results: 
Median time delay between research PET and surgery was 2days.  SUV and TBR values for 
the symptomatic plaques and the asymptomatic contralateral carotid arteries/plaques show 
no significant difference (n=19, p-value >0.10), regardless of quantification method.  
Intraclass correlation coefficient was >0.8 in all measures of carotid artery/plaque uptake 
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(SUV) and >0.6 in almost all measures of target-to-background ratio (TBR). None of the 
excised plaques were shown to contain cells (macrophages, lymphocytes, vessel-associated 
cells) expressing sst2 on their cell membrane.  
 
Conclusion: 
Ga68 DOTATATE activity on PET in recently symptomatic carotid plaques is not significantly 
different to contralateral carotids/plaques. Any activity seen on PET is not shown to be from 
specific sst2 receptor-mediated uptake in-vitro. It is therefore unlikely that sst2 PET/CT 
imaging will have a role in the detection and characterization of symptomatic carotid plaques. 
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INTRODUCTION 
Atherosclerosis is a leading cause of mortality and morbidity. There is the concept that while 
atherosclerotic plaques may contribute to symptoms by luminal stenosis, it is the disruption of 
unstable plaques, which leads to catastrophic events, including stroke and myocardial 
infarction. Termed ‘vulnerable plaques’, these unstable plaques are believed to have 
characteristic features such as inflammatory cells infiltration, lipid core and fibrous cap (1,2).   
 
Measuring the degree of luminal stenosis was the mainstay of assessment and 
directed management decisions until recently (3-5).  Recognition of its limitation has driven 
the use of biomarkers such as fractional flow reserve in coronary disease and exploration of 
functional imaging to non-invasively identify vulnerable plaques (6,7).     
 
Radionuclide imaging has the advantageous capability of directly probing molecular 
mechanisms in-vivo using radioactive tracers (8).  In particular, assessment of plaque 
inflammation using F18-FDG (flurodeoxyglucose) PETCT (positron emission 
tomography/computed tomography) has been extensively studied.   Since early validation 
studies (9,10), plaque F18-FDG uptake has been associated with cardiovascular risk factors 
and circulating inflammatory markers (11,12).  It can predict future cardiovascular risk in 
asymptomatic individuals (13) and early stroke recurrence (14).  Further studies have shown 
its potential in evaluating treatment response with statins (15).  Moreover, FDG PET has 
become the primary endpoint in some drug trials assessing the drugs’ anti-inflammatory 
effect (16,17).  Despite the success, extension of its use to coronary vessels is limited by 
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variably high background myocardial FDG activity.  This has fueled motivation to explore 
alternative PET tracers (18).  
 
Inflammatory cells involved in the pathophysiology of atherosclerosis (19) may 
express somatostatin receptors (20,21). It is also known that vessels can express 
somatostatin receptors under certain conditions (22,23). Recently, two preclinical murine 
studies have demonstrated potential of somatostatin receptor PET in atherosclerosis imaging 
(24,25).  Retrospective human studies with these tracers have also shown promise (26-29).  
In this study, we prospectively explored the use of a clinically established PET tracer, 
Gallium68-[1,4,7,10-tetraazacyclododecane-N,N’,N’’,N9’’’-tetraacetic acid]-D-Phe1,Tyr3-
octreotate (Ga68-DOTATATE), a somatostatin receptor ligand, in patients whom are believed 
to have vulnerable carotid plaques, based on recent symptomatic events.  We hypothesized 
that Ga68-DOTATATE uptake is measurably higher on PETCT in vulnerable carotid plaques, 
compared to contralateral carotid arteries/plaques.  We assessed two quantification methods, 
adapted from previous carotid PET tracer-histological validation studies.  Inter-observer and 
intra-observer agreement were tested.  As a secondary imaging endpoint, we studied the 
relationship of PET uptake with plaque composition on CT angiogram (CTA). This latter had 
been shown to correlate well with histology (30). Finally, we studied the subsequently excised 
carotid endarterectomy samples with emphasis on somatostatin subtype-2 (sst2) 
immunohistochemistry.   
 
 
MATERIALS AND METHODS 
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Patients 
Institutional review board approved this study. All subjects signed a written informed 
consent.  20 consecutive consenting patients were recruited.  Inclusion criteria were patients 
planned for carotid endarterectomy for recent symptomatic events (stroke, transient 
ischaemic attack or amauroxis fugax).  They were identified from well-established regional 
hyperacute stroke unit and transient ischaemic attack clinics.  As per local routine, the 
diagnosis was confirmed by specialist stroke physicians. Other potential mechanisms of 
these symptoms were reasonably excluded. These patients had >70% carotid stenosis 
confirmed by two concordant imaging modalities of CTA down to aortic arch, magnetic 
resonance angiogram or duplex ultrasound. These were interpreted by local experts using 
the European Carotid Surgery Trial and North American Symptomatic Carotid 
Endarterectomy grading for carotid stenosis (4,5).  The patients’ management was fully 
discussed at multidisciplinary board meetings attended by specialist stroke physicians, 
vascular surgeons and neuroradiologists, Here, the etiology of the presumed carotid events 
was scrutinized.  Consensus was made in this forum, that vulnerable carotid plaque was the 
likely culprit, and that the patient was deemed at high risk for further events. Plan for carotid 
endarterectomy was agreed here.  Only cases clearly attributed to the carotid and high risk 
were considered for this study.  Exclusion criteria were age <45, pregnancy and lactation and 
inability to consent.  
 
Imaging 
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All patients underwent Ga68-DOTATATE PET/CT prior to surgery. An additional 
CTA was performed at the same time for superior coregistration of Ga68-DOTATATE uptake 
and carotid plaque, unless precluded by renal failure. 
 
Synthesis and labelling of Ga68-DOTATATE has been published previously (31).  
Our radiopharmacy has an average radiochemical purity of 99% (range 98-99.9%) for this 
tracer.  Patients were given Ga68-DOTATATE injection (mean activity received 157MBq) 
with uptake time of 60 minutes.  All PETCT were performed on the same scanner 
(DiscoveryVCT, GE Healthcare).  A single bed acquisition was performed to image the 
carotid arteries.  CT parameters were: 120kVp, mA modulation 30-300mAs, noise index 20, 
pitch 1.375, rotation time 800msec, pixel size 0.98mm and 2.5mm slice thickness. This was 
followed by an emission scan with 3D acquisition over 4 minutes, iterative reconstruction 
(OSEM 20 subset 2 iterations), 3.27mm slice thickness and 5.5mm pixel size. Attenuation 
correction was performed with the non-contrast CT. CTA was performed as published 
previously (32). 
 
PET Analysis 
There is no established method for quantification of Ga68-DOTATATE PET in this 
context.  We drew on previous published carotid PET tracer-histological validation studies for 
the two methods used (10,32,33).  Images were analyzed using Xeleris (GE Healthcare).  
Carotid plaques were identified using CTA as part of this study, or in a few patients with renal 
failure, from imaging acquired at the time of their acute presentation day(s) prior to the 
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research PETCT.  The location of the carotid plaques on PET was identified by either fusing 
the PET and CTA images or by reviewing the imaging side-by-side.  
  
Plaque uptake was measured by drawing ROI around the carotid arteries at every 
slice, where (i) plaques were visible, and (ii) around the carotid bifurcation (up to 2cm 
superior and 1cm inferior to the bifurcation).  If no clear plaque was seen on a given slice (as 
was often the case on the asymptomatic side, on eventual unblinding of reader), ROI was 
placed around the carotid arteries at the same axial slices as any contralateral carotid plaque 
to allow comparison.  In each ROI, the mean and maximum standardized uptake values 
(SUV) were calculated (Bq/mL).  Average blood pool activity for each patient was derived 
from averaging at least three different ROI in venous structures, usually at the most 
distended segment of the jugular vein. 
 
Measurements from the ROI were computed in two different ways to reflect two 
different quantification methods of Ga68-DOTATATE uptake: 
 
Volume plaque method:  mean and maximum pixel activities for the ROI in all the 
slices in a plaque/vessel defined above were averaged to give ‘SUVmean’ & ‘SUVmax’ of the 
plaques.  These were also corrected for blood pool activity, by division by the average blood 
pool activity, to derive target-to-background measurements: ‘TBRmean’ & ‘TBRmax’. 
 
Most intense pixel/ROI method: the single pixel with the most intense signal and the 
ROI with the most intense averaged SUV value in a plaque/vessel were selected.  These 
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were designated ‘maxSUVmax’ and ‘maxSUVmean’.  These were corrected for blood pool 
activity as above to derive ‘maxTBRmax’ & ‘maxTBRmean’.         
 
 
Inter- and Intra-Observer Variability  
To assess intra-observer variability, PET analysis was performed twice by reader 1, 
a PET accredited radiologist with interest in cardiovascular imaging, with an 8 week period in 
between.  Inter-observer variability was assessed by a further analysis by reader 2, a 
superintendent radiographer with prior experience in similar carotid PET quantification.  The 
two readers co-read several pilot studies (not included in this study) to establish a standard 
protocol for analysis.  All images were analyzed with the readers blinded to the side of 
symptoms.   
 
Plaque Composition Analysis  
Carotid plaques on the symptomatic side were manually segmented slice-by-slice 
on the CTA using ADW (GE Healthcare) workstation. The lumen was segmented out 
manually. Plaque composition in individual pixel was assigned based on density (Hounsfield 
unit of 20-60 were assigned as lipid, 60-130 as fibrous, and >130 as calcification) (32,34). 
Plaque components were expressed as percentage of overall plaque volume. 
 
Histological Analysis 
All patients proceeded to have carotid endarterectomy using an eversion 
endarterectomy technique, by one of three dedicated surgeons on next available list. Plaques 
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were immediately fixed in 10% buffered formalin and decalcified following standard protocol 
at University College London Hospitals. Specimens were transversely sectioned at 5-mm 
intervals, embedded face up in paraffin, and cut at 3-4-μm thickness.  Haematoxylin and 
eosin sections were obtained and the plaque was typed according to American Heart 
Association criteria (2). Pan-macrophage marker immunostaining (CD68) was performed as 
previously described (32). 
 
Sst2 immunohistochemistry was performed at the University of Berne, where there 
is established expertise in somatostatin immunohistochemistry, as previously published using 
sst2 antibody UMB1 (35). Tissues known to express sst2 (neuroendocrine tumours, germinal 
centres and peritumoral vessels) were used as positive controls (21,23). Sst2 
immunohistochemistry has been selected because Ga-DOTATATE is known to be highly 
selective for sst2 labeling (36). There is no reason to believe that it would label another sst 
subtype in these tissues.  Samples were sent from London to Berne in batches, with 10 
randomly selected samples initially, followed by batch of 3 specifically selected for their 
highest Ga68-DOTATATE signals on PETCT.  
 
Statistical Analysis 
Statistical tests were performed using SPSS version 21.  Statistical significance was 
assigned for p<0.05.  Normality of measurements was tested with Shapiro-Wilk test and 
visual inspection.  Two-tailed paired sample t-test was used to compare uptake between the 
symptomatic and asymptomatic sides.  Intra-class correlation coefficient was used to assess 
intra-observer variability (1-way random effects model with absolute agreement) and inter-
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observer variability (2-way mixed effects model with absolute agreement) (37).  Spearman 
rank correlation was used to assess relationship of PET signal with CT plaque components, 
and Kruskal-Wallis test for the relationship of immunohistochemistry with PET signal.   
 
 
RESULTS  
Patient demographics, risk factors and medications are presented on Table 1. All excised 
symptomatic plaques were considered advanced by American Heart Association histological 
criteria (type V or VI).  Detailed histological features are presented on Supplemental Table 1.  
 
Imaging Findings 
One patient had focal intense uptake in the asymptomatic carotid bifurcation, 
corresponding to a previously un-diagnosed carotid body tumour.  This patient was excluded.  
There was no statistically significant difference between symptomatic carotid plaques and 
asymptomatic carotid plaques/arteries (Fig. 1) in any of the SUV and TBR measurements 
(Table 2; Fig. 2; Supplemental Fig. 1 and 2).  
 
All values for SUV measurements are >0.9, with narrow confidence intervals, 
indicating excellent agreement.  Values for TBR measurements are almost exclusively >0.6, 
indicating substantial agreement.  (Supplemental Table 2).  
 
There was no statistically significant correlation between any SUV and TBR 
parameters with the CT plaque composition parameters (Supplemental Table 3). 
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 Immunohistochemistry Findings 
Variable CD68 staining was observed in the excised plaques, at values comparable 
to previous carotid plaque imaging-histological investigations (32) (Supplemental Table 1). 
There was no statistically significant relationship of CD68 with any SUV and TBR parameters 
(Supplemental Table 4).  
 
None of the tissues were shown to contain cells expressing sst2 on their cell 
membrane (Figure 3), a major criteria for G-protein coupled receptor specificity (28). 
Moreover, no non-specific labeling, i.e. no cytoplasmic staining of the cells, was detected in 
the analyzed tissues.   
 
DISCUSSION 
 In this prospective study of Ga68-DOTATATE PETCT with histological validation 
of human vulnerable carotid plaques, we addressed the pertinent question of whether sst2 
expressing cells (believed to be macrophages) are present in these plaques, in sufficient 
density for detection with Ga68-DOTATATE PET/CT in vivo.  We demonstrated that 
measurement of vascular uptake with Ga68-DOTATATE PETCT in carotid plaques was 
feasible, using two different PET quantification methods, with both showing substantial to 
excellent agreements.  However, we did not find significantly higher Ga68-DOTATATE 
activity in vulnerable carotid plaques, compared to the contralateral carotids/plaques. Sst2-
immunohistochemistry was chosen for its established, direct relevance to Ga68-
DOTATATE-sst2 binding at the cell surface (in contrast to mRNA/PCR or macrophage 
cluster of differentiation markers).  Despite confirmation of the presence of CD68+ 
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macrophages, none of the excised plaques examined showed cells expressing sst2 on 
their cell membrane, indicating that there is no molecular basis for an sst2 receptor 
mediated uptake of somatostatin tracer in vitro in acute human plaques.  Our findings 
would not support the use of Ga68-DOTATATE in the detection and characterization of 
vulnerable plaques in human.   
 
Rationale for Study of Ga68-DOTATATE in Atherosclerosis 
Monocytes and macrophages were the first inflammatory cells to be associated 
with atherosclerosis. They are believed to play important roles in its pathogenesis, 
contributing to necrotic core formation and fibrous cap thinning in advanced 
atherosclerosis, features thought to confer ‘vulnerability’ (19,38).   It is known that human 
macrophages express sst2 on their cell surface in cell culture experiments (20,39).   Ga68-
DOTATATE, a specific sst2 receptor agonist, therefore was thought to have the potential to 
be a surrogate marker of inflammation to study plaque biology.  This has been recently 
validated in two preclinical murine experiments (apolipoprotein -/- mice model) at a tissue 
level (24,25).   
 
Human Studies with Somatostatin Receptor PET 
Four recent studies examined the potential role of these in atherosclerosis, 
retrospectively in patients with neuroendocrine tumours.  
 
One found significant correlation between TBR with calcific plaque burden and 
prior vascular events (26).  Another found that TBR at areas of focal vessel uptake are 
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higher in patients with more cardiovascular risk factors (27).  A further study found increase 
Ga68-DOTATATE uptake in coronary plaques compared to normal coronary segments 
(28).  The last compared Ga68-DOTATOC and Cu64-DOTATATE (29), in correlating 
vessel uptake against cardiovascular risk factors.  Cu64-DOTATATE demonstrated higher 
uptake compared to Ga68-DOTATOC, with positive correlation with Framingham scores 
only with Cu64-DOTATATE, but not with Ga68-DOTATOC.   
 
To our knowledge, there has been one prospective study specifically looking at 
vulnerable plaque (40). This examined 10 patients with stroke or transient ischaemic attack 
with Cu64-DOTATATE.  The authors found higher uptake in the symptomatic plaque 
compared to the contralateral carotid vessel.  Significant but weak association was 
demonstrated between uptake on PET and CD163 and CD68 gene expression in 
endarterectomy samples on univariate analysis, with CD163 remaining significant on 
multivariate analysis.  CD163 is believed to be a marker of M2 (alternatively activated) 
macrophages, found in haemorrhagic zones of plaques and possibly has an anti-
inflammatory function. 
 
Interpretation in Context of Published Literature 
The preclinical promise has not translated into a positive result in our study. A 
plausible explanation may be species-specific variability of sst subtype expression. For 
instance, human chronic atherosclerotic popliteal arteries were found to show consistently 
higher sst1 expression compared to sst2 or sst4, which differed from the predominant 
sst2&3 expression in rat vessels (41). In addition, although macrophage activation is a 
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feature of inflammation in atherosclerosis development, there are conflicting results in the 
published preclinical human cell experiments as to whether sst2 expression on 
macrophages signifies their activation (20,25,39).  Our validation on human vulnerable 
plaques is more directly relevant to clinical practice. Our results would suggest lack of 
significant sst2 expression in macrophages present in recently symptomatic plaques. 
 
Our study also adds to current knowledge in that unlike our study, the 
retrospective studies above did not allow study of causation, or molecular mechanism of 
any observed tracer activity, to the clinical parameters observed.  These were also 
performed in patients with chronic plaques only.  It should be noted that plaque FDG 
uptake has been shown to evolve over the chronic course of disease (42).  It is likely that 
Ga68-DOTATATE uptake would behave similarly.  One of the retrospective studies (27) 
showed poor co-localization of FDG and Ga68-DOTATATE signal in vessels. FDG activity 
in plaques is established as a surrogate marker of plaque inflammation, validated against 
macrophage cell surface marker (CD68) in a number of studies (9,10).  Poor co-localization 
of the Ga68-DOTATATE and FDG signal therefore raises serious question about the 
meaning of any observed DOTATATE (& FDG) signal.  The only published prospective 
study on Cu64-DOTATATE did not examine sst2 expression in the resected tissue (40).   
 
Taken together, it is likely that there are complex relationships between stage of 
plaque evolution (chronic versus acute), macrophage density and activity, sst subtype 
expression, FDG and somatostatin receptor PET signal. Macrophage subtype/activation in 
vulnerable human atherosclerosis plaques have been studied recently in vitro, generally 
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showing higher expression of pro-inflammatory M1 macrophages compared to M2 
macrophages, which may be anti-atherogenic (43-45). How this interacts with Ga68-
DOTATATE signal needs to be further explored.   
 
 
Limitations  
Our sample size is small and this raises possibility of false negative study. 
However our negative imaging findings were supported by robust histological examination 
of ex-vivo samples, performed in a laboratory with long held expertise in sst receptor 
studies.  The antibodies used was the current gold standard of sst2 immunostaining which 
had been extensively evaluated previously (35,46). Moreover, our sample size was 
comparable to other similar carotid imaging-histological validation investigations (10,18,33). 
There is heterogeneity of time between carotid event, research PET and endarterectomy in 
our patients.  This reflects the logistical challenge surrounding patient recruitment, tracer, 
scanner and operating theatre availability. However, the ranges of delay are comparable 
with similar studies.  We performed single time point imaging at 60 minutes only.  Bulk of 
the retrospective data on vascular DOTATATE PET uptake had similar uptake time.  In 
addition, an ‘early’ scan ([median] 85 minutes) with Cu64-DOTATATE has already been 
shown to be preferred, compared to delayed acquisition (40). 
 
Ga68 has less optimal imaging characteristics compared to F18 or Cu64. Ga68 
DOTATATE may be less sensitive to weak differences in uptake compared to equivalent 
Cu64 labelled tracers (29).  Higher image noise is reflected by poorer inter- and intra-
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observer agreement of TBR measurements, in face of excellent agreement in SUV 
measurements – while the arterial plaques provide a clear target for directing ROI 
placement, ROI for blood pool may be more operator dependent; image noise and variation 
in blood pool measurements therefore manifest as poorer TBR agreement.  Increasing 
acquisition time beyond 4 minutes may counter this, but at the expense of risk of 
detrimental patient movement and misregistration.  
 
Spillover & partial volume effect from adjacent structures is a concern, with major 
salivary glands and thyroid shown to have SUVmax of 2.3-4.2(31), higher than vascular 
activity observed.  There may also be increased activity in adjacent nodes.  ROI were 
drawn carefully to minimize these.  
 
 
CONCLUSION 
We demonstrated feasibility of Ga68-DOTATATE measurement of carotid 
plaques on PETCT.  However, we found no significant difference in Ga68DOTATATE 
activity in symptomatic carotid plaques compared to the asymptomatic side.  This finding 
was supported by compelling lack of sst2 expression on excised plaques.  Our findings 
indicate no molecular basis for an sst2 receptor mediated uptake of the somatostatin tracer 
in vitro and would not support use of Ga68-DOTATATE PET in assessment of acute 
vulnerable human plaques.   
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FIGURES 
 
 
Figure 1. Images from a 68‐year‐old male with multiple recent left amaurosis fugax.  A,B: CTA shows severe 
stenosis of the left internal carotid artery extending from the bifurcation; D,E: fused and PET image at this 
level;  C,F:  segmented  plaque  on  CTA  from  a  different  level,  with  colour  coded  scale  showing  plaque 
compositions. 
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Figure  2.  Box  whisker  plots  showing  no  significant  difference  in  SUV  and  TBR  parameters  between  the 
symptomatic and the asymptomatic side.  
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Figure  3:  Sst2  immunohistochemistry  showing  absence  of  sst2  in  a  representative  carotid  plaque.  A: 
Hematoxylin‐eosin staining of a representative part of the plaque (insert shows the whole plaque). B: Sst2 
immunohistochemistry  of  adjacent  section  showing  absence  of  sst2.  C:  Sst2  immunohistochemistry  at 
higher magnification. D‐F: Positive sst2  immunohistochemistry  in 3 different  reference control  tissues: D: 
neuroendocrine  tumor  cells.  E:  Lymphocytes  in  gut  germinal  centre.  F:  Endothelial  cells  in  peritumoral 
vessel. Bars = 0.1 mm. 
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TABLES  
Table 1.  
Characteristics  Value 
Age(years: mean+/‐standard deviation)  78.5+/‐9.5 
Sex(male:female)  12:8 
Time between symptom to 
PETCT(days:median;range) 
6.5;2‐27 
Time between PETCT to endarterectomy( 
days:median;range) 
2;0‐6 
Diagnosis    
Stroke   40% 
Transient ischaemic attack  30% 
Amauroxis fugax  30% 
Cardiovascular Risk Factors    
Hypertension  85% 
Smoker  45% 
Previous transient ischaemic attack/stroke   35% 
Previous ischaemic heart disease  40% 
Diabetes  30% 
Atrial fibrillation   15% 
Hypercholesterolaemia  65% 
Medications at presentation   
Aspirin  
Clopidogrel  
Warfarin 
Statins 
Ezetimibe 
40% 
10% 
10% 
55% 
15% 
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Table 2. SUV and TBR between the symptomatic and the asymptomatic sides. 
Volume plaque method  
SUVmax  SUVmean  TBRmax  TBRmean 
p‐value  0.223  0.784  0.507  0.707 
 
Most intense pixel/ROI method 
  maxSUVmax  maxSUVmean  maxTBRmax  maxTBRmean 
p‐value  0.098  0.897  0.248  0.810 
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SUPPLEMENTAL DATA 
 
Supplemental Table 1. Histological type (American Heart Association criteria) and features of 
excised plaques & CD68 result 
Patient 
Number  Plaque type 
Lipid 
core Thrombus 
Intraplaque 
haemorrhage Ulceration CD68 
1 Vb Yes No No No >15% 
2 VI Yes No No Yes >15% 
3 VI Yes No No Yes 5-15% 
4 Vb Yes No No No 5-15% 
5 Vb Yes No No No >15% 
6 Va No No No No <5% 
7 Va No No No No 5-15% 
8 VI Yes No Yes Yes >15% 
9 Va Yes No No No >15% 
10 Va Yes No No No >15% 
11 VI Yes No No Yes >15% 
12 Vb No No No No 5-15% 
13 VI No No No Yes 5-15% 
14 Vb No No No No <5% 
15 Vb No No No No 5-15% 
16 Vb Yes No No No 5-15% 
17 Vc No No No No 5-15% 
18 VI Yes No Yes No >15% 
19 VI Yes No No Yes <5% 
20 Vb Yes No No No >15 
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Supplemental Table 2. Intraclass correlation coefficient 
  
 Volume plaque method Intra-observer  Inter-observer* 
Endarterectomy  SUVmax 0.98(0.94-0.99) 0.97(0.91-0.99) 
  SUVmean 0.98(0.96-0.99) 0.98(0.95-0.99) 
  TBRmax 0.71(0.41-0.87) 0.61(0.25-0.83) 
  TBRmean 0.75(048-0.89) 0.63(0.25-0.84) 
Contralateral  SUVmax 0.98(0.96-0.99) 0.97(0.90-0.99) 
  SUVmean 0.99(0.98-1.00) 0.98(0.97-1.00) 
  TBRmax 0.80(0.57-0.92) 0.63(0.26-0.84) 
  TBRmean 0.83(0.61-0.93) 0.72(0.38-0.89) 
 
  
 Most intense pixel/ROI value method Intra-observer  Inter-observer* 
Endarterectomy  maxSUVmax 0.94(0.85-0.98) 0.96(0.88-0.98) 
  maxSUVmean 0.95(0.89-0.98) 0.93(0.84-0.97) 
  maxTBRmax 0.70(0.40-0.87) 0.61(0.24-0.83) 
  maxTBRmean 0.82(0.61-0.93) 0.48(0.03-0.76) 
Contralateral maxSUVmax 0.99(0.97-1.00) 0.95(0.84-0.98) 
  maxSUVmean 0.99(0.97-1.00) 0.97(0.93-0.99) 
  maxTBRmax 0.79(0.55-0.92) 0.77(0.46-0.91) 
  maxTBRmean 0.84(0.64-0.94) 0.73(0.40-0.89) 
 
*excludes 1 outlier 
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Supplemental Table 3. CT plaque composition analysis & correlation with Ga68DOTATATE uptake parameters. 
  
% Plaque 
Volume 
  Volume Plaque Method Most intense pixel/ROI method 
    
SUV 
max 
SUV 
mean 
TBR 
max 
TBR 
mean 
maxSUV
max 
maxSUVm
ean 
maxTBR
max 
maxTBR
mean 
Lipid 32.3+/-10.3 
r-value -0.49 -0.49 -0.08 0.02 -0.37 -0.43 0.03 0.10 
    p-value 0.06 0.06 0.78 0.95 0.17 0.11 0.92 0.72 
                
Fibrous 42.5+/-10.6 
r-value -0.12 -0.08 0.05 0.43 -0.04 -0.04 0.01 0.44 
    p-value 0.68 0.79 0.85 0.11 0.89 0.90 0.96 0.10 
                
Calcification  25.2+/-14.7 
r-value 0.28 0.24 0.00 -0.34 0.18 0.19 -0.03 -0.36 
    p-value 0.31 0.39 0.99 0.22 0.52 0.49 0.91 0.18 
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Supplemental Table 4.  Relationship between CD68 immunohistochemistry with Ga68DOTATATE uptake parameters. 
 
 
Volume Plaque Method Most intense pixel/ROI method 
 
SUV 
max 
SUV 
mean 
TBR 
max 
TBR 
mean 
maxSUV 
max 
maxSUV 
mean 
maxTBR 
max 
maxTBR 
mean 
         p-value 0.74 0.81 0.9 0.83 0.42 0.68 0.33 0.54 
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Supplemental Figure 1.   Further box plots showing comparison of further PET derived parameters between the symptomatic plaque 
and contralateral side. A,B: SUVmean and TBRmean from the volume plaque method; C,D: maxSUVmean and maxTBRmean from the 
most intense pixel/ROI method.  (see main text). 
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Supplemental Figure 2.  Example plot of 2 parameters showing individual patient data. (Plots for other parameters not shown).   
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